EMA Authorised: Cabazitaxel Accord (cabazitaxel) — Accord Healthcare S.L.U.

View source ↗

Summary

The European Medicines Agency authorised Cabazitaxel Accord for castration-resistant prostate cancer. The marketing authorization holder is Accord Healthcare S.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cabazitaxel Accord (cabazitaxel)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms, Castration-Resistant. MAH: Accord Healthcare S.L.U.. Decision date: 07/01/2026